Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Identification of novel therapeutic targets for the treatment of STAG2 deficient cancers
EF 2017-18
Résumé
Effective cancer therapy takes advantage of the biological difference between cancer cells and neighbouring healthy cells. Tumours frequently have somatic mutations that are not present in normal cells. These tumour-specific mutations can be exploited to specifically target tumour cells for killing. That is, the tumour mutations define an Achilles heel (relative to adjacent normal tissue). A Synthetic Lethal (SL) interaction between two genes is defined when an alteration in either gene alone is viable, but alterations in both genes simultaneously are lethal. The protein product of a gene that has a SL interaction with a tumour-specific mutation would be an excellent anti-cancer drug target allowing the indirect targeting of non-druggable cancer mutations and providing great selectivity, since by definition, healthy cells lacking the cancer-specific lesion would not be sensitive. The concept of exploiting SL interactions as a targeted cancer therapy has recently come into the mainstream.Cohesin is a highly-conserved molecular complex that has crucial roles in chromosomal stability, chromatin architecture, transcriptional regulation, replication fork integrity, and DNA repair. Cohesin components are frequently mutated across a range of tumour types. Despite this association, no strategy targeting cohesin defects has been developed. We are using high throughput genetic tools in yeast to identify SL genetic interactions with cohesin mutations, which can then be tested in human tumour cells. These SL partner genes may suggest cross-species candidate proteins in humans that when inhibited (e.g. by a drug) would specifically kill tumor cells relative to normal cells.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386589
Name
Komm Kristopher
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of novel therapeutic targets for the treatment of STAG2 deficient cancers
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Budding Yeast; Cancer; Chromosome Instability; Cohesion; Synthetic Cytotoxicity; Synthetic Lethality
Abstract
Effective cancer therapy takes advantage of the biological difference between cancer cells and neighbouring healthy cells. Tumours frequently have somatic mutations that are not present in normal cells. These tumour-specific mutations can be exploited to specifically target tumour cells for killing. That is, the tumour mutations define an Achilles heel (relative to adjacent normal tissue). A Synthetic Lethal (SL) interaction between two genes is defined when an alteration in either gene alone is viable, but alterations in both genes simultaneously are lethal. The protein product of a gene that has a SL interaction with a tumour-specific mutation would be an excellent anti-cancer drug target allowing the indirect targeting of non-druggable cancer mutations and providing great selectivity, since by definition, healthy cells lacking the cancer-specific lesion would not be sensitive. The concept of exploiting SL interactions as a targeted cancer therapy has recently come into the mainstream.Cohesin is a highly-conserved molecular complex that has crucial roles in chromosomal stability, chromatin architecture, transcriptional regulation, replication fork integrity, and DNA repair. Cohesin components are frequently mutated across a range of tumour types. Despite this association, no strategy targeting cohesin defects has been developed. We are using high throughput genetic tools in yeast to identify SL genetic interactions with cohesin mutations, which can then be tested in human tumour cells. These SL partner genes may suggest cross-species candidate proteins in humans that when inhibited (e.g. by a drug) would specifically kill tumor cells relative to normal cells.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Komm, Kristopher
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~